Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers.
about
Primary Graft Dysfunction after Lung TransplantationLung transplantation in IIP: A reviewPrimary graft dysfunction: lessons learned about the first 72 h after lung transplantationLung transplantation for cystic fibrosisGeographic distance between donor and recipient does not influence outcomes after lung transplantation.Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation.Plasma cytokines and chemokines in primary graft dysfunction post-lung transplantation.Effects of methylprednisolone on inflammatory activity and oxidative stress in the lungs of brain-dead rats.Construct validity of the definition of primary graft dysfunction after lung transplantation.Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis.Method of isolated ex vivo lung perfusion in a rat model: lessons learned from developing a rat EVLP program.Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction.eComment. Re: Radiological patterns of primary graft dysfunction after lung transplantation.Increased Intraoperative Fluid Administration Is Associated with Severe Primary Graft Dysfunction After Lung TransplantationThe relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia.Clinical risk factors for primary graft dysfunction after lung transplantationPrimary graft dysfunction.The clinical potential of ex vivo lung perfusion.Physician assistant model for lung procurements: a paradigm worth consideringEx vivo lung perfusion in clinical lung transplantation--state of the art.Role of genetics in lung transplant complications.Protein biomarkers associated with primary graft dysfunction following lung transplantation.Successful emergent lung transplantation after remote ex vivo perfusion optimization and transportation of donor lungs.Quantitative Evidence for Revising the Definition of Primary Graft Dysfunction After Lung Transplant.Role of biomarkers in early infectious complications after lung transplantation.A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation.Onset of Inflammation With Ischemia: Implications for Donor Lung Preservation and Transplant Survival.Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors.Expression profiling of human donor lungs to understand primary graft dysfunction after lung transplantation.Evaluating acellular versus cellular perfusate composition during prolonged ex vivo lung perfusion after initial cold ischaemia for 24 hours.Plasma intercellular adhesion molecule-1 and von Willebrand factor in primary graft dysfunction after lung transplantation.Organ preservation: from the past to the future.Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction.
P2860
Q26745629-A5EB4A62-B9C6-4B51-87FA-700A2AA74823Q26774870-0FAA887C-62EF-4BBD-8A14-0F09FA2A8761Q28084783-7646D51F-6233-498A-872C-D03B002784A1Q28749501-FBAA2B4D-6B6F-4640-B33A-21F54DB65B5CQ30424172-8FA9EA8B-481E-4766-AA68-5EBE9F52F220Q33650349-8F994A94-CF74-4C6D-8133-1741C7A1729EQ33653089-DD7AF429-5905-472C-BB08-791B7C13DA6CQ33823934-30789EF5-A4D1-411B-A512-17280BC0736DQ34238666-1395BA72-121F-49E8-8958-0218636AC3AFQ35127935-1D7BB0D5-2881-4276-8391-B8AAB62B627BQ35162339-A116C1F2-76BD-4E38-AAF5-2DFB9A4BD95FQ35855114-9D9CAA03-EB9F-43C1-9463-264E2801C7F0Q35961927-FC797872-55D8-429D-A0E3-2904D0B418AAQ36709286-1B21D7D2-CA8D-4AAB-9A58-51A6F989413DQ36768114-45C0AA38-6374-4186-8834-AF8D5056D1F9Q37070008-AC16CBFA-29F1-41C9-AD1C-64C85556192AQ37670609-1C766C9A-FF5A-4DF4-A9A2-F8C883291F51Q37979247-1DB381B4-3815-4E92-A591-4B3F00041255Q38148817-77E3945E-4043-477D-ADF8-899704846660Q38233850-7F7BBCB4-65D9-4802-B787-89F2339D0213Q38376217-FC39B20F-E4CA-4570-B113-09BE59E1C75EQ39107058-E3B7E0BE-25DF-4DB0-ADA7-190B433963C4Q39223375-FBDAA8AF-0811-48DD-BAB5-6B3B21DC9D7FQ40057755-911E16DC-79E4-4849-9905-7D87E3BFA83DQ40136113-01E6CC56-CCAF-42B2-AFE7-3977B8A7DB49Q46003287-AAA99C2A-A1E4-4818-8E04-F95103B0F47AQ46576466-BACFE30E-B8E3-41B6-A946-67135D2ACBFAQ48556223-7A1B4CA3-C3E1-491F-AD50-B705E4D67A45Q50915479-DFE348EA-13BD-4BD5-B04B-943F69475A97Q51604820-49B0E7BD-7D51-4BA5-99F7-6EB78E2DFE7EQ51904878-EFBD06EB-085B-4340-A8B2-71CFF0D2F39BQ52643107-9B81B35E-6C84-44FD-AC4D-4D3E08AD117FQ53242921-B9B57540-29D1-40AA-9BAB-2DAC98ACE2BD
P2860
Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part III: donor-related risk factors and markers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@ast
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
type
label
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@ast
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
prefLabel
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@ast
Report of the ISHLT Working Gr ...... ated risk factors and markers.
@en
P2093
P1476
Report of the ISHLT Working Gr ...... lated risk factors and markers
@en
P2093
David McGiffin
Geert M Verleden
ISHLT Working Group on Primary Lung Graft Dysfunction
Octavio Pajaro
Rebecca Menza
Robert S Bonser
Rosemary F Kelly
Stephan Schueler
P304
P356
10.1016/J.HEALUN.2005.02.017
P577
2005-08-08T00:00:00Z